RT Journal Article
SR Electronic
T1 Analysis of immunization time, amplitude, and adverse events of seven different vaccines against SARS-CoV-2 across four different countries
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.03.11.22272153
DO 10.1101/2022.03.11.22272153
A1 Romero-Ibarguengoitia, Maria Elena
A1 González- Cantú, Arnulfo
A1 Pozzi, Chiara
A1 Levi, Riccardo
A1 Mollura, Maximiliano
A1 Sarti, Riccardo
A1 Sanz-Sánchez, Miguel Angel
A1 Rivera-Salinas, Diego
A1 Hernández-Ruíz, Yodira Guadalupe
A1 Armendariz-Vázquez, Ana Gabriela
A1 Del Rio-Parra, Gerardo Francisco
A1 Barco-Flores, Irene Antonieta
A1 González-Facio, Rosalinda
A1 Azzolini, Elena
A1 Barbieri, Riccardo
A1 de Azevedo Dias, Alessandro Rodrigo
A1 Henriques-Guimaraes, Milton
A1 Bastos-Borges, Alessandra
A1 Acciardi, Cecilia
A1 Paez-Bo, Graciela
A1 Teixeira, Mauro Martins
A1 Rescigno, Maria
YR 2022
UL http://medrxiv.org/content/early/2022/03/13/2022.03.11.22272153.abstract
AB Background Scarce information exists in relation to the comparison of seroconversion and adverse events following immunization (AEFI) with different SARS-CoV-2 vaccines. Our aim was to correlate the magnitude of the antibody response to vaccination with previous clinical conditions and AEFI.Methods A multicentric comparative study where SARS-CoV-2 spike 1-2 IgG antibodies IgG titers were measured at baseline, 21-28 days after the first and second dose (when applicable) of the following vaccines: BNT162b2 mRNA, mRNA-1273, Gam-COVID-Vac, Coronavac, ChAdOx1-S, Ad5-nCoV and Ad26.COV2. Mixed model and Poisson generalized linear models were performed.Results We recruited 1867 subjects [52 (SD 16.8) years old, 52% men]. All vaccines enhanced anti-S1 and anti-S2 IgG antibodies over time (p<0.01). The highest increase after the first and second dose was observed in mRNA-1273 (p<0.001). There was an effect of previous SARS-CoV-2 infection; and an interaction of age with SARS-CoV-2, Gam-COVID-Vac and ChAdOx1-S (p<0.01). There was a negative correlation of Severe or Systemic AEFI (AEs) of naïve SARS-CoV-2 subjects with age and sex (p<0.001); a positive interaction between the delta of antibodies with Gam-COVID-Vac (p=0.002). Coronavac, Gam-COVID-Vac and ChAdOx1-S had less AEs compared to BNT162b (p<0.01). mRNA-1273 had a higher number of AEFIs. The delta of the antibodies showed an association with AEFIs in previously infected individuals (p<0.001).Conclusions The magnitude of seroconversion is predicted by age, vaccine type and SARS-CoV-2 exposure. AEs are correlated with age, sex, and vaccine type. The delta of the antibody response is positively correlated with AEs in patients previously exposed to SARS-CoV-2.Registration number NCT05228912Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis research was conducted using private funding from Techint Group of Companies.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics committee/local Institutional Review Board from the school of Medicine from Universidad de Monterrey gave ethical approval: Ref.:26022021-CN-1e-CII confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors(AEFI)Adverse events following immunization(AEs)Severe adverse events